The 5-5-5 Adaptive Bridging Radiation Therapy (ABRT) trial is a pilot study aimed at improving the logistics, time, cost, and side effects associated with radiation therapy in patients with relapsed or refractory B-cell lymphoma. Given the increasing adoption of CAR T-cell therapies in hematological malignancies, this study could enhance patient outcomes and streamline treatment protocols. If successful, the findings may position Massachusetts General Hospital as a leader in innovative treatment approaches, potentially attracting partnerships with pharmaceutical companies and radiation therapy device manufacturers, such as Varian Medical Systems, which is already collaborating on this trial. The market for CAR T-cell therapies is substantial, with ongoing demand for improved pre-treatment regimens, suggesting a favorable commercial outlook for successful implementation of the ABRT protocol.